SCHEMBL360364

SCHEMBL360364

CCn1cc(-n2ccc(=O)c(COc3ccc4ncc(-c5ccc(N6CCOCC6)nc5)cc4c3)n2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.42
LRRK2 Q5S007 1/20 0.39
FGFR1 P11362 2/20 0.37
FGFR2 P21802 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
SYK P43405 4/20 0.36
ERN1 O75460 2/20 0.35
PDE10A Q9Y233 1/20 0.35
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CNR2 P34972 1/20 0.34
HPGD P15428 1/20 0.34
PPARD Q03181 2/20 0.34
FGFR4 P22455 1/20 0.34
CSF1R P07333 1/20 0.34
KIT P10721 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368924 0.84 GRM2 (0.38) GRM2LRRK2FGFR1FGFR2FGFR3
SCHEMBL10283774 0.84 LRRK2 (0.36) LRRK2FGFR1FGFR2FGFR3KDR
SCHEMBL368322 0.84 PDGFRB (0.41) GRM2LRRK2FGFR1FGFR2FGFR3
SCHEMBL368139 0.84 PDGFRB (0.39) GRM2LRRK2FGFR1FGFR2FGFR3
SCHEMBL10283523 0.84 MET (0.39) LRRK2
SCHEMBL370955 0.83 MET (0.38) LRRK2PPARGPPARA
SCHEMBL14916103 0.83 GRIN2B (0.36) LRRK2FGFR1FGFR2FGFR3KDR
SCHEMBL359863 0.83 PDGFRB (0.34) GRM2LRRK2FGFR1FGFR2FGFR3
SCHEMBL371343 0.83 PDGFRB (0.45) GRM2LRRK2FGFR1FGFR2FGFR3
SCHEMBL14915783 0.82 JAK2 (0.38) LRRK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET GRM2 696/4885LRRK2 510/4885FGFR1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.